On April 16, AstraZeneca (AZN.US) announced the latest exploratory analysis results of the phase 3 clinical trial TOPAZ-1.
The Zhitong Finance App learned that on April 16, AstraZeneca (AstraZeneca/AZN.us) announced the latest exploratory analysis results of the phase 3 clinical trial TOPAZ-1. The data showed that its major immunotherapy Imfinzi in combination with standardized treatment provided clinically significant long-term overall survival (OS) benefits to patients with advanced biliary tract cancer (BTC) at 3 years. The survival rate of patients treated with Imfinzi combination therapy at 3 years was more than double that of the chemotherapy group alone (14.6% compared to 6.9%).
Imfinzi is a humanized monoclonal antibody. It binds to PD-L1 protein and blocks the interaction of PD-L1 with PD-1 and CD80 proteins to fight tumor immune escape strategies, remove suppression of immune responses, and enhance the immune system's ability to kill cancer cells.